Latest News

Breast Cancer - Clinical Research - Anticancer Agents - Immunotherapy

Pembrolizumab–Trastuzumab May Offer PANACEA For Trastuzumab-Resistant Breast Cancer

  • 13 Feb 2019
  • Author : By Lynda Williams, Senior medwireNews Reporter

For patients with advanced HER2-positive breast cancer who have progressed on trastuzumab, combining the HER2 inhibitor with pembrolizumab may be an effective option...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof Pembrolizumab–Trastuzumab May Offer PANACEA For Trastuzumab-Resistant Breast Cancer

Breast Cancer - Anticancer Agents

Disease-Free Survival ‘Appropriate’ Surrogate Endpoint For HER2-Positive Early Breast Cancer

  • 31 Jan 2019
  • Author : By Lynda Williams, Senior medwireNews Reporter

Overall survival can be successfully predicted from disease-free survival for women with HER2-positive early breast...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof Disease-Free Survival ‘Appropriate’ Surrogate Endpoint For HER2-Positive Early Breast Cancer

Immunotherapy - Complications/Toxicities of Treatment

PD-1 Inhibitor Efficacy Predicted By Immune-Related Adverse Events

  • 30 Jan 2019
  • Author : By Lynda Williams, Senior medwireNews Reporter

Patients who experience immune-related adverse events during nivolumab or pembrolizumab monotherapy may have a higher chance of achieving an objective response than those who do not...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof PD-1 Inhibitor Efficacy Predicted By Immune-Related Adverse Events

Haematological Malignancies - Clinical Research - Anticancer Agents - Immunotherapy

Ibrutinib Plus Nivolumab May Be ‘Promising’ For CLL Richter’s Transformation

  • 21 Jan 2019
  • Author : By Lynda Williams, Senior medwireNews Reporter

Combining ibrutinib with nivolumab achieved clinical response in chronic lymphocytic leukaemia patients with Richter’s transformation...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof Ibrutinib Plus Nivolumab May Be ‘Promising’ For CLL Richter’s Transformation

Cancer in Special Situations

Undiagnosed HBV, HCV Infection Rate At Cancer Diagnosis Warrants Screening

  • 18 Jan 2019
  • Author : By Lynda Williams, Senior medwireNews Reporter

Screening for hepatitis B and C viral infection at time of cancer diagnosis may be helpful...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof Undiagnosed HBV, HCV Infection Rate At Cancer Diagnosis Warrants Screening

Oesophageal Cancer - Surgical Oncology

Hybrid Minimally Invasive Oesophagectomy May Reduce Resection Complications

  • 11 Jan 2019
  • Author : By Lynda Williams, Senior medwireNews Reporter

Morbidity and mortality among oesophageal cancer patients undergoing resection may be prevented by switching to a hybrid minimally invasive procedure...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof Hybrid Minimally Invasive Oesophagectomy May Reduce Resection Complications

Non-Small Cell Lung Cancer - Immunotherapy - Complications/Toxicities of Treatment

Autoimmune Markers Linked To Immunotherapy Efficacy, Adverse Events

  • 03 Jan 2019
  • Author : By Shreeya Nanda, Senior medwireNews Reporter

Researchers say that testing for autoimmune antibodies before initiating checkpoint inhibitor therapy could aid in determining the risk–benefit ratio for patients with advanced non-small-cell lung cancer...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof Autoimmune Markers Linked To Immunotherapy Efficacy, Adverse Events

Renal Cell Cancer - Anticancer Agents - Surgical Oncology

SURTIME Indicates Role For Sunitinib Before Cytoreductive Nephrectomy In mRCC Patients

  • 18 Dec 2018
  • Author : By Shreeya Nanda, Senior medwireNews Reporter

Immediate surgery may not be the best option for patients with metastatic renal cell carcinoma...

view detailsof SURTIME Indicates Role For Sunitinib Before Cytoreductive Nephrectomy In mRCC Patients

Immunotherapy - Complications/Toxicities of Treatment

Rare Haematological irAEs Reported For PD-1, PD-L1 Inhibitor Use

  • 11 Dec 2018
  • Author : By Lynda Williams, Senior medwireNews Reporter

A database review has identified a small risk of severe haematological immune-related adverse events among cancer patients using PD-1 and PD-L1 inhibitors...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof Rare Haematological irAEs Reported For PD-1, PD-L1 Inhibitor Use

Haematological Malignancies - Lymphomas - Immunotherapy

2-Year ZUMA-1 Results Add Support For Axicabtagene Ciloleucel In Refractory Large B-Cell Lymphoma

  • 05 Dec 2018
  • Author : By Shreeya Nanda, Senior medwireNews Reporter

Long-term follow-up of axicabtagene ciloleucel-treated patients with refractory large B-cell lymphoma suggests a role for the chimeric antigen receptor T-cell therapy in this setting...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof 2-Year ZUMA-1 Results Add Support For Axicabtagene Ciloleucel In Refractory Large B-Cell Lymphoma

Haematological Malignancies - Lymphomas - Immunotherapy

High Response Rates With Tisagenlecleucel In Adult Refractory DLBCL Patients

  • 04 Dec 2018
  • Author : By Shreeya Nanda, Senior medwireNews Reporter

Phase II trial findings add support for the use of chimeric antigen receptor T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof High Response Rates With Tisagenlecleucel In Adult Refractory DLBCL Patients

Central Nervous System Malignancies - Complications/Toxicities of Treatment - Radiation Oncology

Low Risk Of Intracranial Malignancy After Stereotactic Radiosurgery

  • 30 Nov 2018
  • Author : By Shreeya Nanda, Senior medwireNews Reporter

Incidence of radiation-associated intracranial malignancy following stereotactic radiosurgery is comparable to that of primary intracranial tumours in the general population...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof Low Risk Of Intracranial Malignancy After Stereotactic Radiosurgery

Bone Sarcomas - Anticancer Agents

Regorafenib Shows ‘Clinically Meaningful’ Activity For Metastatic Osteosarcoma

  • 29 Nov 2018
  • Author : By Lynda Williams, Senior medwireNews Reporter

Patients with progressive metastatic osteosarcoma may respond to second- or later-line treatment with regorafenib...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof Regorafenib Shows ‘Clinically Meaningful’ Activity For Metastatic Osteosarcoma

Prostate Cancer - Anticancer Agents - Surgical Oncology - Radiation Oncology

High-Risk Prostate Cancer Survival Might Be Comparable With Surgical, Non-Surgical Strategies

  • 21 Nov 2018
  • Author : By Lynda Williams, Senior medwireNews Reporter

Gleason 9–10 prostate cancer patients may derive similar survival from combination treatments using surgical and nonsurgical approaches...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof High-Risk Prostate Cancer Survival Might Be Comparable With Surgical, Non-Surgical Strategies

Head and Neck Cancers - Anticancer Agents - Radiation Oncology

Cetuximab Regimen Inferior To Cisplatin For HPV-Positive Oropharyngeal Carcinoma

  • 19 Nov 2018
  • Author : By Lynda Williams, Senior medwireNews Reporter

Cisplatin plus radiation offers better survival outcomes and no worse toxicity than cetuximab plus radiation for patients with HPV-positive oropharyngeal carcinoma...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof Cetuximab Regimen Inferior To Cisplatin For HPV-Positive Oropharyngeal Carcinoma